| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 7 Aug 2025 | 31 Jul 2025 |
| Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2025. The Board of Directors of the company at their meeting held on 07th August, 2025 have inter-alia considered and approved the unaudited standalone & consolidated financial results for the quarter ended 30th June, 2025 (As Per BSE Announcement Dated on: 07/08/2025) | ||
| Board Meeting | 20 May 2025 | 14 May 2025 |
| Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve Audited financial results for the quarter and year ended 31st March 2025 The Outcome of the Board Meeting held on 20th May, 2025 is enclosed herewith. (As Per BSE Announcement Dated on :20.05.2025) | ||
| Board Meeting | 28 Apr 2025 | 28 Apr 2025 |
| In compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you about the outcome of the Board Meeting held on 28/04/2025 | ||
| Board Meeting | 28 Mar 2025 | 28 Mar 2025 |
| Disclosure under Regulation 30 - Change in management Disclosure under Regulation 30 - Acquisition Disclosure under Regulation 30 - Appointment of Secretarial Auditor | ||
| Board Meeting | 10 Feb 2025 | 3 Feb 2025 |
| Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31st December 2024. In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today have inter-alia, considered and approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and nine months ended 31st December, 2024. Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed herewith. The Board Meeting commenced at 03:00 p.m. (IST) and concluded at 07:15 p.m.(IST). (As Per Bse Announcement Dated on 10.02.2025) | ||
| Board Meeting | 9 Nov 2024 | 4 Nov 2024 |
| Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Saturday 09th November 2024 to inter alia consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2024. In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report Trading by Insiders the trading window for dealing with securities of the Company is closed from Tuesday the 01st October 2024 to Monday the 11th November 2024 (both days inclusive). In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved : 1. Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended 30th September, 2024. Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed herewith. 2. Changes in the Senior Management of the Company : a. Categorization of Dr. Chandrashekhar Mainde, Technical Director as the Senior Management Personnel of the Company. b. Categorization of Dr. Uttam Kedar, Assistant Vice President - R&D as the Senior Management Personnel of the Company. The Board Meeting commenced at 03:00 p.m. and concluded at 06:15 p.m. (As Per BSE Announcement Dated on: 09/11/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.